Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.53 |
| ▸ | TK1 | P04183 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | ALB | P02768 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | TYMP | P19971 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL5709986 | 1.00 | TK1 (0.58) | TK1LMNATSHRALBBLM | |
| Phosphoric Acid SCHEMBL5147665 | 1.00 | TK1 (0.58) | TK1LMNATSHRALBBLM | |
| Phosphoric Acid SCHEMBL7977953 | 1.00 | TK1 (0.58) | TK1LMNATSHRALBBLM | |
| SCHEMBL925743 | 0.95 | LMNA (0.58) | TK1LMNATSHRALBBLM | |
| SCHEMBL22992337 | 0.95 | LMNA (0.58) | TK1LMNATSHRALBBLM | |
| SCHEMBL14596607 | 0.95 | LMNA (0.58) | TK1LMNATSHRALBBLM | |
| SCHEMBL13286394 | 0.95 | LMNA (0.58) | TK1LMNATSHRALBBLM | |
| SCHEMBL762579 | 0.95 | LMNA (0.58) | TK1LMNATSHRALBBLM | |
| SCHEMBL23485 | 0.95 | LMNA (0.58) | TK1LMNATSHRALBBLM | |
| SCHEMBL14421795 | 0.95 | LMNA (0.58) | TK1LMNATSHRALBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250369027-A1 | SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS | TWIST BIOSCIENCE CORP (US) | 2025-12-04 | — | — | US | claimed |
| CN-119677866-A | Substrate cleavage for nucleic acid synthesis | 特韦斯特生物科学公司 | 2025-03-21 | — | — | CN | claimed |
| EP-4504959-A1 | SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS | Twist Bioscience Corporation (US) | 2025-02-12 | — | — | EP | claimed |
| US-20240344057-A1 | METHODS OF SYNTHESIZING OLIGONUCLEOTIDES USING TETHERED NUCLEOTIDES | Twist Bioscience Corporation | 2024-10-17 | — | — | US | claimed |
| WO-2023196499-A1 | SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS | Twist Bioscience Corporation (US) | 2023-10-12 | — | — | WO | claimed |
| EP-4229210-A1 | METHODS OF SYNTHESIZING OLIGONUCLEOTIDES USING TETHERED NUCLEOTIDES | Twist Bioscience Corporation (US) | 2023-08-23 | — | — | EP | claimed |
| WO-2022086866-A1 | METHODS OF SYNTHESIZING OLIGONUCLEOTIDES USING TETHERED NUCLEOTIDES | Twist Bioscience Corporation (US) | 2022-04-28 | — | — | WO | claimed |
| US-20260132223-A1 | CLEAVABLE LINKERS FOR THE TETHERING OF POLYMERASES TO NUCLEOTIDES | ANSA BIOTECHNOLOGIES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4731762-A2 | DE NOVO STEPWISE TEMPLATE-INDEPENDENT SYNTHESIS OF LONG POLYNUCLEOTIDES | Ansa Biotechnologies, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20250369027-A1 | SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS | TWIST BIOSCIENCE CORP (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4594480-A2 | CLEAVABLE LINKERS FOR THE TETHERING OF POLYMERASES TO NUCLEOTIDES | Ansa Biotechnologies, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024073349-A9 | CLEAVABLE LINKERS FOR THE TETHERING OF POLYMERASES TO NUCLEOTIDES | ANSA BIOTECHNOLOGIES, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-119677866-A | Substrate cleavage for nucleic acid synthesis | 特韦斯特生物科学公司 | 2025-03-21 | — | — | CN | disclosed |
| EP-3458465-A1 | LABELED NUCLEOTIDE COMPOSITIONS AND METHODS FOR NUCLEIC ACID SEQUENCING | Quantum-si Incorporated (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10174363-B2 | Methods for nucleic acid sequencing | Quantum-Si Incorporated (US) | 2019-01-08 | — | — | US | disclosed |
| EP-3298389-A1 | METHOD OF DETERMINING THE SEQUENCE OF A NUCLEAR ACID USING TIME RESOLVED LUMINESCENCE | Quantum-si Incorporated (US) | 2018-03-28 | — | — | EP | disclosed |
| US-20170362651-A1 | LABELED NUCLEOTIDE COMPOSITIONS AND METHODS FOR NUCLEIC ACID SEQUENCING | Quantum-Si Incorporated (US) | 2017-12-21 | — | — | US | disclosed |
| WO-2017201514-A1 | LABELED NUCLEOTIDE COMPOSITIONS AND METHODS FOR NUCLEIC ACID SEQUENCING | Quantum-Si Incorporated (US) | 2017-11-23 | — | — | WO | disclosed |
| US-20170107562-A1 | METHODS FOR NUCLEIC ACID SEQUENCING | Quantum-Si Incorporated (US) | 2017-04-20 | — | — | US | disclosed |
| WO-2016187580-A1 | METHOD OF DETERMINING THE SEQUENCE OF A NUCLEAR ACID USING TIME RESOLVED LUMINESCENCE | Quantum-Si Incorporated (US) | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132223-A1 | CLEAVABLE LINKERS FOR THE TETHERING OF POLYMERASES TO NUCLEOTIDES | POLN, PCNA, POLB | ADRA1A 4746/4885TK1 76/4885LMNA 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.